In follicular lymphomas with the t(14;18) translocation, there is increased expression of the bcl-2 gene, which is dependent upon regulatory elements within the bcl-2 5 0 flanking region and the immunoglobulin heavy-chain gene enhancers. We found that t(14;18) lymphomas expressed C/EBPa, which is not normally expressed in B lymphocytes. Expression of C/EBPa increased bcl-2 expression, and two regions of the bcl-2 P2 promoter that mediated this effect were identified. C/EBPb was also able to increase bcl-2 promoter activity through these sites. The 5 0 site was GC-rich and did not contain a C/EBP consensus sequence; however, C/EBP was observed to interact with this site both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. The 3 0 region contained the Cdx site, which mediates the effect of A-Myb on the bcl-2 promoter. In vivo binding studies revealed that C/EBP interacted with this region of the bcl-2 promoter as well. Decreased expression of C/EBP factors due to targeting of their transcripts by siRNA molecules resulted in downregulation of Bcl-2 protein. We conclude that C/EBPa and C/EBPb contribute to the deregulated expression of Bcl-2 in t(14;18) lymphoma cells.
Introduction
The bcl-2 gene is translocated into the immunoglobulin heavy-chain locus in the majority of follicular lymphomas. As a result of this t(14;18) translocation, bcl-2 is expressed in a deregulated manner, which results in high levels of bcl-2 mRNA and protein (Cleary et al., 1986) . The elevated level of Bcl-2 in t(14;18) lymphoma cells increases their survival and protects them from apoptosis (Graninger et al., 1987) . The mechanisms involved in the deregulated expression of bcl-2 are not entirely clear, but several transcription factors that play a role have been identified.
Two promoters, P1 (5 0 ) and P2 (3 0 ), mediate the initiation of bcl-2 transcription (Seto et al., 1988) . In normal B cells, the 5 0 promoter is the most active one while both the 5 0 and 3 0 promoters are active in transcription of the translocated bcl-2 gene. We have shown previously that a cAMP-response element site is required for the expression of bcl-2 in normal B cells and in t(14;18) B cells. CREB proteins mediate this activity (Ji et al., 1996; Wilson et al., 1996) , but we have recently found that NF-kB activates bcl-2 expression through this site as well (Heckman et al., 2002) . A binding site for the Cdx homeodomain protein is important for the activity of the P2 promoter in t(14;18) lymphoma cells. Our studies demonstrated that A-Myb and Cdx2 interacted with the Cdx site to activate the P2 promoter (Heckman et al., 2000) . It appeared that A-Myb and Cdx2 were components of a larger complex that formed at the Cdx site in the bcl-2 promoter (Heckman et al., 2000) . Further investigations focused on transcription factors that were known to interact with either Myb or Cdx proteins. In this study, we identify C/EBP proteins as components of this complex.
The C/EBP family of transcription factors plays an important role in the regulation of cell proliferation and differentiation. Six different family members share substantial sequence identity in the C-terminal basic leucine zipper region, and dimerization mediated by the basic region is required for DNA binding. Tissue-and cell-specific expression is observed for many of the C/EBP family members. C/EBPa is expressed at high levels in the liver, adipose tissue, lung, intestine, and peripheral blood mononuclear cells (Lekstrom-Himes and Xanthopoulos, 1998; Ramji and Foka, 2002) . It is required for myeloid differentiation beyond the myeloblast stage (Zhang et al., 1997) . C/EBPb is also expressed in the liver, intestine, lung, adipose tissue and in the spleen, kidney, and myelomonocytic cells (Ramji and Foka, 2002) . Mice deficient in C/EBPb show impaired generation of B lymphocytes, suggesting that C/EBPb plays an important role in B lymphopoiesis (Chen et al., 1997) . C/EBP family members interact and cooperate with a number of other transcription factors, including p50 (LeClair et al., 1992) , Myb (Oelgeschlager et al., 1996; Verbeek et al., 1999; Tahirov et al., 2002) , CREB/ATF (Vallejo et al., 1993) , and AP-1 (Hsu et al., 1994) .
We now describe the positive regulation of bcl-2 promoter activity by C/EBPa and C/EBPb. Although C/EBPa is not normally expressed in B cells, we show that it is expressed in t(14;18) lymphoma cell lines. Transfection of a C/EBPa expression vector into a t(14;18) lymphoma cell line increased the amount of endogenous bcl-2 mRNA and protein. Conversely, transfection with siRNA molecules targeting C/EBP decreased Bcl-2 levels. We found that C/EBP mediated this activity through two sites in the bcl-2 P2 promoter, one of which was the Cdx site.
Results

C/EBPa expression in t(14;18) cells
The C/EBP family members exhibit a broad range of tissue-and cell-stage-specific expression patterns. In B cells, C/EBPb and C/EBPg are the major contributors to C/EBP-mediated transcription (Cooper et al., 1994) . While C/EBPb expression is critical for B-cell development and activation, the negative regulatory activity of C/EBPg is important in immature B cells. To determine which C/EBP family members were expressed in t(14;18) cells, we performed Western blotting with the t(14;18) cell line DHL-4. For comparison, we also examined the mature B-cell line DHL-9 and the pre-B cell line Nalm-6. Expression of four C/EBP family members was examined: C/EBPa, -b, -d, and -g. Oct-1 expression was also assessed to ensure equivalent protein loading. Interestingly, the t(14;18) cell line was found to express C/EBPa, C/EBPb, and C/EBPd, while C/EBPg was almost undetectable (Figure 1 ). Although the Nalm-6 and DHL-9 cells expressed C/EBPb and C/EBPd, C/EBPa protein was not detected in these cells (Figure 1 ). Examination of another t(14;18) cell line, DHL-6, revealed that it also expressed C/EBPa (data not shown). These results provide the first evidence indicating that C/EBPa is expressed in certain types of B cells.
Increased endogenous Bcl-2 expression in C/EBPa-transfected cells
Since expression of C/EBPa has not been previously described in B cells, we wished to determine if transfection of an expression vector encoding this transcription factor could affect endogenous Bcl-2 expression in t(14;18) cells. In addition, we wished to examine whether C/EBPb also regulated Bcl-2 expression. Given that the transfection efficiency of DHL-4 cells is low, we cotransfected the cells with the pHook2 vector and selected the transfected cells with haptencoated magnetic beads. The selected cells were then analysed by Western blot to assess protein expression. When cells were transfected with a C/EBPa expression vector, an increase of approximately 25% in C/EBPa protein was detected along with a similar increase in Bcl-2 (Figure 2a) . Although a 65% increase in C/EBPb was detected in the cells transfected with the C/EBPb expression vector, no significant increase in Bcl-2 protein expression was detected (Figure 2b ). To determine if a change in bcl-2 mRNA expression could be detected, RNA was collected from the selected cells, and cDNA was prepared. Relative bcl-2 mRNA expression was quantitated by a real-time PCR assay. As shown in Figure 2c , a 2.5-fold increase in bcl-2 transcripts was observed in the C/EBPa-transfected cells as compared to cells transfected with an empty expression vector, while only a slight increase in bcl-2 transcripts was detected in the C/EBPb-transfected cells.
Identification of two C/EBP responsive regions in the bcl-2 promoter A schematic representation of the bcl-2 5 0 flanking and untranslated regions with previously characterized transcription factor binding sites is shown in Figure 3a . Cotransfection of the full-length bcl-2 promoter with a C/EBPa expression vector resulted in an approximate threefold increase in promoter activity, while increased activation was observed with a construct containing only the P2 promoter (Figure 3b) . Cotransfection of the C/EBPa expression vector with reporter constructs containing deletions of the bcl-2 P2 promoter resulted in the identification of two C/EBPa responsive regions within that promoter (Figure 3b ). The first responsive region, or 5 0 region, was between bases À1278 and À1251 and contained a very GC-rich sequence exhibiting no homology to any known transcription factor binding sites, including C/EBP. The second responsive region, or 3 0 region, was between bases À324 and À297 and contained a previously identified Cdx binding site, but no C/EBP site. Similar results were obtained when the reporter constructs were cotransfected with the C/EBPb expression vector (data not shown).
In vitro protein interaction with the C/EBP responsive regions
The C/EBP family members typically bind as dimers to DNA containing the consensus sequence Although the 5 0 C/EBP responsive region did not contain a C/EBP consensus sequence or any other known transcription factor binding site, we wished to characterize the proteins interacting with this region by EMSA. Specific protein binding was observed using DHL-4 nuclear extract and a labeled probe representing this sequence (Figure 4a, lane 1) . Formation of the protein complex could be inhibited by competition with a 100-fold molar excess of cold wild-type probe, as well as with a 100-fold molar excess of unlabeled DNA containing the C/EBP consensus sequence (Figure 4a , lanes 2 and 3). As the Myb family of transcription factors can also regulate bcl-2 through the P2 promoter, and they have been shown to cooperate with the C/EBP family members, competition with unlabeled DNA containing the Myb consensus sequence was also performed. However, no competition was observed with this sequence or a nonspecific sequence (Figure 4a , lanes 4 and 5). Interestingly, protein complex formation was also inhibited by incubation with an antibody specific for C/EBPa and was supershifted with an antibody specific for the transcription cofactor CBP (Figure 4a , lanes 6 and 7), but no change was observed upon incubation with an antibody specific for the bcl-2 P2 regulator A-Myb, or an antibody specific for a nontranscription factor protein ( Figure 4a , lanes 8 and 9). Additionally, no change in protein complex formation was observed with incubation with a C/EBPbspecific antibody (data not shown). Nevertheless, these observations indicate that C/EBPa and its cofactor CBP interact with this C/EBP responsive region.
We have shown that the Cdx binding site, which is contained in the 3 0 C/EBP responsive region, is required for the activation of bcl-2 by A-Myb (Heckman et al., 2000) . As the direct interaction of A-Myb with this sequence was not demonstrated, we believed that AMyb cooperated with other factors such as Cdx to regulate bcl-2 expression. Interestingly, a number of studies have shown that the Myb transcription factors interact and cooperate with the C/EBP family members to activate transcription (Oelgeschlager et al., 1996; Verbeek et al., 1999; Tahirov et al., 2002) . Similar to the 5 0 C/EBP responsive region, the 3 0 region did not contain a C/EBP consensus sequence. The specific protein complex that formed when DHL-4 nuclear extract was incubated with the labeled sequence ( Figure 4b , lane 1) could be competed away with a 100-fold molar excess of unlabeled C/EBP consensus sequence (Figure 4b , lane 4) as well as with a 100-fold molar excess of unlabeled Myb consensus sequence (Figure 4b , lane 6). This was similar to the competition seen with a 100-fold molar excess of the unlabeled wildtype sequence (Figure 4b, lane 2) . No competition was observed with a 100-fold molar excess of unlabeled sequence containing a mutation to the Cdx site, sequence with a mutated C/EBP site, sequence with a mutated Myb site, or with a nonspecific sequence (Figure 4b, lanes 3, 5, 7, and 8) . However, no change in complex formation was observed with the addition of antibodies specific for C/EBPa, C/EBPb, or A-Myb (data not shown). Although the lack of complex change using the C/EBP and A-Myb antibodies could be an indication that these proteins are not binding to this region, the ability of the consensus sequences to compete away the complex suggests otherwise. Further studies were designed to determine the identity of the proteins that bound in vivo.
Identification of proteins interacting in vivo with the C/EBP responsive regions
Although the EMSA performed on the 5 0 C/EBP responsive region in the bcl-2 P2 promoter provided clear evidence of the interaction of C/EBPa and CBP with that site in vitro, the exact identity of the proteins interacting with the 3 0 site was unclear. To identify the proteins interacting with these two regions and to assess protein interaction with these sequences in vivo, we used the chromatin immunoprecipitation (ChIP) assay as described by Boyd and Farnham (1999) . In this assay, proteins were crosslinked to DNA by treatment of DHL-4 cells with formaldehyde. The crosslinked chromatin was then extracted and broken down to an average length of 500 bp by sonication. The sheared chromatin was subjected to immunoprecipitation using antibodies specific for C/EBPa, C/EBPb, A-Myb, CBP, or IgG, which was used as a nonspecific control. The final immunoprecipitates were washed, and the proteins and RNA were degraded. The DNA products were subjected to PCR amplification using two sets of primers specific for the two C/EBP responsive regions. The first set of primers produced a 207-bp amplicon from À1361 to À1154 and encompassed the 5 0 C/EBP responsive region. Antibodies specific for C/EBPa, C/EBPb, or CBP resulted in the precipitation of this region, but an antibody specific for A-Myb or IgG did not select for this site ( Figure 5 ). For the 3 0 C/EBP responsive region, a second set of primers was used to amplify a 177-bp sequence from À395 to À218. Immunoprecipitation with antibodies specific for C/EBPa, C/EBPb, CBP, and A-Myb all resulted in the selection of the 3 0 responsive region, but an anti-IgG antibody did not ( Figure 5 ). As an additional control, the precipitates were used to amplify a 161-bp irrelevant sequence within the bcl-2 promoter; however, no amplification was observed except with the total input sample ( Figure 5 ). These results indicate that both C/EBPa and C/EBPb, along with the transcription cofactor CBP, interact with both the 5 0 and 3 0 responsive regions in vivo, while A-Myb interacts with the 3 0 responsive region.
A GC-rich sequence and a Cdx binding site mediate C/EBP positive regulation of the bcl-2 promoter
As shown by deletion analysis, two regions mediated the positive regulation of the bcl-2 promoter by C/EBPa and C/EBPb. Neither region contained a C/EBP consensus sequence although both interacted with C/EBPa and C/EBPb. The GC-rich 5 0 region did not contain any known transcription factor binding sites, but if this region was deleted (Figure 6a ), the ability of C/EBPa to activate the bcl-2 P2 promoter was reduced from nine-fold to five-fold (Figure 6b) . If the Cdx site in the 3 0 responsive region was mutated, C/EBPa activation of bcl-2 was reduced to four-fold (Figure 6b ). Very little transactivation was observed with a reporter construct in which the 5 0 region was deleted and the Cdx site was mutated (Figure 6b ). Similar activities were observed when the C/EBPb expression vector was cotransfected with the mutant reporter constructs (data not shown). These results indicate that both the GC-rich 5 0 region and the Cdx site in the 3 0 region are required for the ability of C/EBP to activate bcl-2 expression.
siRNA molecules targeting C/EBP transcripts decrease C/EBP and Bcl-2 expression
To further confirm the relation between C/EBP and Bcl-2 expression, we constructed small-interfering RNA (siRNA) molecules targeting either C/EBPa or C/EBPb transcripts. These molecules were incorporated into an RNA-induced silencing complex (RISC) that enzymatically degrades the target transcripts. When DHL-4 cells were transfected with siRNA molecules targeting C/ EBPa, a reduction of approximately 53% in C/EBPa protein was observed along with a 65% decrease in Bcl-2 protein compared to cells transfected with nonspecific siRNA (Figure 7a ). Cells transfected with siRNA targeting C/EBPb transcripts expressed approximately 47% less C/EBPb protein and 37% less Bcl-2 compared to cells transfected with nonspecific siRNA (Figure 7b) . Therefore, by decreasing the amount of C/EBPa or -b in DHL-4 cells, we can also decrease the amount of Bcl-2.
Discussion
In these studies, we demonstrated that C/EBP family members play a role in the regulation of bcl-2 expression in t(14;18) lymphoma cells. While expression of C/EBPb has been observed in B cells, C/EBPa expression has promoter. Chromatin proteins and DNA were crosslinked by formaldehyde treatment in DHL-4 cells, the crosslinked chromatin was collected and sheared, and then fractionated using specific antibodies as indicated. The positive control is represented by the total input fraction. Negative controls included a no chromatin sample, no antibody sample, and nonspecific IgG. The precipitated DNA was analysed by PCR using primers that amplified a 207-bp product for the 5 0 C/EBP responsive region or a 177-bp product for the 3 0 C/EBP responsive region. As a control, a 161-bp sequence representing an irrelevant region in the bcl-2 promoter was also amplified using the precipitated DNA and specific primers. The PCR products were visualized by ethidium bromide staining of a 2% agarose gel not. We found that C/EBPa was expressed in t(14;18) lymphoma cell lines and that C/EBPb was expressed as expected. Since the C/EBP family members form heterodimers that differ in their transactivation potential, the expression of C/EBPa in t(14;18) lymphoma cells may lead to differential expression of C/EBP target genes in these cells. C/EBPa is thought to be a stronger transcriptional activator than C/EBPb (Poli, 1998) . There were two regions in the bcl-2 P2 promoter that were responsive to C/EBP. The 5 0 site was located at À1278 to À1251 and did not contain a C/EBP consensus sequence. C/EBP bound this site in vitro as shown by EMSA and in vivo as demonstrated by ChIP assay. We have no clear evidence at this time that another protein directly binds to this site with C/EBP, although this would be a reasonable assumption. The second responsive site was the Cdx site, which we have previously shown was important for regulation of the bcl-2 P2 promoter by A-Myb. Both C/EBP and Myb consensus sequences competed for binding to this site in EMSA. Based on these results and our previous studies, the protein complex that binds to the Cdx site contains Cdx, A-Myb, and C/EBP. The reason for the lack of a supershift in EMSA with the C/EBP antibody at this site is not entirely clear. It is likely that there are a number of proteins binding to this region, and perhaps this combination of proteins is not particularly stable in an in vitro assay. In addition, the C/EBP and Myb transcription factors may interact with the Cdx binding site in an indirect manner, which is not readily detectable by EMSA or supershift experiments. We have not been able to observe a supershift with the A-Myb antibody, even with the Myb consensus sequence. Further studies showed that both C/EBP and A-Myb bound in vivo by ChIP assay. It is possible that the protein complex is more stable after fixation of the cells, and this could explain the detection of both C/ EBP and A-Myb at this site by ChIP. At both sites, we were also able to detect the in vivo interaction of the histone acetyltransferase CBP, a cofactor for C/EBP and Myb family members. The functional significance of both of these sites was demonstrated by a decrease in bcl-2 promoter activity with deletion or mutation of the C/EBP responsive sites.
Cotransfection of a C/EBPa expression vector resulted in increased bcl-2 mRNA and protein, while cotransfection with C/EBPb did not. The full-length bcl-2 promoter was activated to a similar level as the endogenous bcl-2 mRNA by cotransfection of C/EBPa. A greater activation of the bcl-2 P2 promoter alone by C/EBPa was observed, which may reflect the presence of negative regulatory regions in the P1 promoter (Chen and Boxer, 1995; Heckman et al., 1997) . The fact that cotransfection of C/EBPb did not increase bcl-2 expression may be due to the higher level of expression of endogenous C/EBPb compared to C/EBPa. We thus designed experiments to decrease the level of C/EBPa or C/EBPb and measure the effect on Bcl-2 expression. The results of the siRNA studies demonstrated that both C/EBP family members play a role in the regulation of expression of Bcl-2.
In normal B cells, the bcl-2 P1 promoter is active with very little transcription from the P2 promoter. In t(14;18) lymphoma cells, the P2 promoter is also active. While the mechanisms involved in the activation of the P2 promoter are not entirely clear, it is interesting to note that three transcription factors that are either not normally expressed in B cells (Cdx and C/EBPa) or expressed in only certain subsets of B cells (A-Myb) are involved in the regulation of the P2 promoter. How the expression of these transcription factors occurs in t(14;18) lymphomas is not known; however, NF-kB is involved in the regulation of C/EBPa (Christy et al., 1991; Legraverend et al., 1993) , and t(14;18) lymphoma cells constitutively express nuclear NF-kB (Heckman et al., 2002) . It will be interesting to determine in future experiments if these transcription factors are involved in t(14;18) lymphoma development and could be considered targets for therapy.
Despite the decrease in Bcl-2 levels with inhibition of expression of C/EBP, an increase in apoptosis was not observed (data not shown). Our previous studies have suggested that a decreased level of Bcl-2 in t(14;18) cell lines is not sufficient to induce apoptosis and that additional manipulation of the cells is also required. It is likely that these malignant cells have developed several mechanisms to protect against programmed cell death. Other investigators have observed a role for C/EBP family members in apoptosis. For example, expression of C/EBPz, which can antagonize the function of other C/EBP proteins, resulted in apoptosis of myeloblastic leukemia cell lines (Matsumoto et al., 1996) . Interestingly, the induction of apoptosis was accompanied by downregulation of bcl-2 mRNA, and overexpression of Bcl-2 delayed the induction of apoptosis. No direct connection between the expression of C/EBPz and the downregulation of bcl-2 mRNA was shown, but based on our results, it is possible that this occurred through antagonism of the function of C/EBPa on the bcl-2 promoter. Examination of our t(14;18) cells showed no expression of C/EBPz. It has been shown that C/EBPb can prevent apoptosis during oncogenic Ras signaling in keratinocytes (Zhu et al., 2002) . Investigation of the role of the AML1-ETO fusion product on hematopoiesis revealed that induction of AML1-ETO expression in human myeloid cells resulted in increased apoptosis that was accompanied by both a decrease in Bcl-2 as well as C/EBPa (Burel et al., 2001) . Although the bcl-2 regulatory region contains an AML1 binding site, the decrease in bcl-2 expression was found not to be due to the direct interaction of AML1-ETO with the bcl-2 promoter. A direct relation between bcl-2 promoter activity and C/EBPa expression was not demonstrated. C/EBPa functions as a tumor suppressor in myeloid cells by promoting differentiation and growth arrest Tenen, 2001; Behre et al., 2002) . However, it is intriguing that C/EBPa is expressed in t(14;18) lymphoma cells, and it seems unlikely that it functions as a tumor suppressor in these cells, particularly since it upregulates Bcl-2 expression. In addition, increased levels of C/EBPb in certain types of tumors have been observed (Ondrey et al., 1999; Dearth et al., 2001) , indicating a role for C/EBPb in tumorigenesis. Our results along with those from other investigations demonstrate that the function of C/EBP family members is cell-type specific and complex. Therefore, careful consideration must be given to the development of novel therapies based on the alteration of the level of expression of C/EBP family members.
Materials and methods
Cell lines
DHL-4, Nalm-6, and DHL-9 are human B cell lines that have been described previously (Chen and Boxer, 1995; Ji et al., 1996; Wilson et al., 1996) . All cells were maintained in RPMI medium with 10% fetal calf serum, l-glutamine, penicillin, and streptomycin.
Western blot analysis
For expression of the C/EBP family members in B cells, crude nuclear extracts were prepared from DHL-4, Nalm-6, and DHL-9 cells as described previously (Heckman et al., 2000) . A total of 50 mg of protein was diluted with 2 Â Laemmli buffer and loaded onto a 10% SDS-polyacrylamide gel, electrophoresed, and transferred onto nitrocellulose. Detection of C/EBPa, C/EBPb, C/EBPd, C/EBPg, and Oct-1 was performed using antibodies from Santa Cruz Biotechnology. Western blotting luminol reagent from Santa Cruz Biotechnology was used for chemiluminescence detection. For C/EBP and Bcl-2 expression in selected transfected cells, total protein was collected from the cells by lysing in Triton X-100 extract buffer (10 mm Tris, pH 7.4, 100 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1 mm NaF, 20 mm Na 4 P 2 O 7 , 2mm Na 3 VO 4 , 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mm PMSF).
Detection of specific proteins was carried out as described above. The Bcl-2 and b Tubulin antibodies were obtained from Santa Cruz Biotechnology.
Plasmid constructs
The bcl-2 promoter-luciferase reporter constructs have been described previously (Wilson et al., 1996; Heckman et al., 2000) . Deletions of the bcl-2 5 0 flanking sequence were made by PCR subfragment cloning or by insertion of restriction enzyme sites by site-directed mutagenesis (Stratagene) followed by subfragment cloning. The Cdx site was mutated in the À1278 and À1251 constructs using the Chameleon Double-Stranded Site-Directed Mutagenesis Kit (Stratagene). The primer used for mutagenesis is as follows with the transcription factor site underlined and the mutated bases in boldface: GGGAAACG-CACCTGATTTTTTACTTCGCCGTTTGTTTTTTCTTTA-ACCTTTTCAGC. All plasmid constructs were confirmed by sequencing. The C/EBPa and C/EBPb expression vectors consisted of the human full-length coding regions under the control of the cytomegalovirus (CMV) immediate early promoter. The empty control vector also contained the CMV promoter. The pHook2 vector was obtained from Invitrogen, and the EGFP expression vector was from Clontech.
Transient transfections
For each reporter gene assay and pHook assay, 2 Â 10 7 DHL-4 cells at mid-log phase were pelleted and washed twice with unsupplemented RPMI medium. The cells were resuspended in 0.75 ml of RPMI and mixed with 20 mg DEAE-Dextran. The cells were then placed in a 0.4 cm electroporation cuvette with the appropriate amount of DNA, and electroporation was carried out at 960 mF and 320 V using the Bio-Rad Gene Pulser. The electroporated cells were allowed to recover at 371C in 25 ml supplemented RPMI medium.
Selection of pHook transfected cells
DHL-4 cells were transfected with 10 mg pHook2 vector and 10 mg of C/EBPa, C/EBPb, or empty expression vector. The transfected cells were allowed to recover 18-20 h at 371C, pelleted, resuspended in 1 ml supplemented RPMI medium, and then incubated for 30 min with hapten-coated magnetic beads (Invitrogen) to select for sFV expression. Selected cells were washed three times with supplemented RPMI medium. For the real-time PCR assays, 5000 selected cells were used, and the remaining cells were used for Western analysis as described above.
Quantitation of bcl-2 mRNA expression
Selected transfected cells were pelleted, washed with ice-cold PBS, and the RNA isolated and cDNA prepared using Ambion's Cells-to-cDNA Kit. Real-time PCR was performed on the cDNA using the ABI Prism 7900-HT Sequence Detection System and Universal Master Mix (Applied Biosystems). Bcl-2 and GAPDH expression levels were assessed using the human Bcl-2 and GAPDH Pre-Developed TaqMan Assay Reagents (Applied Biosystems).
Luciferase assays
DHL-4 cells were transfected with 10 mg of reporter DNA, 1 mg of C/EBPa, C/EBPb, or empty expression vector, and 0.1 mg pCMV/b-Gal vector (Applied Biosystems). The transfected cells were allowed to recover at 371C for 24 h, pelleted, washed twice with PBS and lysed in 100 ml 1 Â Dual Light Lysis Buffer (Applied Biosystems). Reporter gene activity was assessed using the Dual-Light Assay System (Applied Biosystems) and on a Femtomaster FB 12 luminometer (Zylux). Results were normalized to b-galactosidase activity.
EMSA
The double-stranded oligonucleotides used for EMSA of the two C/EBP responsive regions in the bcl-2 P2 promoter are shown below. The consensus binding sites are underlined and the mutated sequences are shown in boldface. GGGACACATTATAACGGTTTTTT-AGC CCCTGTGTAATATTGCCAAAAAA-TCG Myb mutated:
GGGACACATGTCTAGCGTTTTTT-AGC CCCTGTGTACAGATCGCAAAAAA-TCG
The oligonucleotides were synthesized with 5 0 overhangs, annealed, and labeled with [a-32 P]dCTP and Klenow polymerase. The binding conditions have been described previously (Heckman et al., 2000) . For DNA competition experiments, a 100-fold molar excess of unlabeled oligonucleotide was added prior to the 20 min room temperature incubation with nuclear extract and labeled probe. For the supershift experiments, 4 mg of antibody was added to the completed binding reaction, and this was incubated for 1 h at 41C. All antibodies were acquired from Santa Cruz Biotechnology. Electrophoresis was performed in a 0.5 Â Tris borate-EDTA 5% polyacrylamide gel at 20 mA and 41C.
ChIP
The ChIP assay was performed as outlined previously (Heckman et al., 2002) . For PCR amplification, the following oligonucleotide sequences were used as primers: ends that would eventually create 3 0 overhanging uridine dimers in the final siRNA, and a 5 0 -CCTGTCTC-3 0 sequence at their 3 0 ends that is complementary to the T7 promoter and is essential for synthesis.
Transfection of siRNA and selection of transfected cells
For each transfection, 5 Â 10 6 DHL-4 cells at mid-log phase were pelleted, washed once with unsupplemented RPMI medium, and then resuspended in 100 ml supplemented Nucleofector Buffer R (Amaxa Biosystems). The cells were placed in an electroporation cuvette with 5 nm siRNA and 1 mg EGFP expression vector and then electroporated in a Nucleofector device (Amaxa Biosystems) using program O-17. The electroporated cells were allowed to recover for 16 h at 371C in 2 ml supplemented RPMI medium. Following incubation, the cells were sorted by GFP expression using a FACSVantage SE cell sorter (BD Biosciences). GFP-positive cells were collected in supplemented RPMI medium, washed with PBS, lysed in Triton X-100 buffer, and protein expression was examined as outlined above.
